Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Want to see XERS full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.01Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong execution: substantial top-line growth (38% total revenue, 43% net product revenue), a near-doubling of Recorlev revenue (95% YoY), improved margins and profitability, and on-track pipeline progress with XP-8121 Phase III planned. Near-term headwinds were limited mainly to Gvoke (flat revenue) due to Medicare resets and increased near-term operating spend tied to deliberate commercial and R&D investments. Overall, positives (robust revenue growth, margin expansion, profitability, guidance raise and pipeline advancement) outweigh the operational and timing headwinds.Company Guidance
Strong Top-Line Growth
Total revenue of $83.1M in Q1'26, up 38% year-over-year; net product revenue of $82.5M, up 43% YoY, driven by Recorlev momentum.
Recorlev Revenue Nearly Doubled
Recorlev net revenue of $49.8M, representing 95% year-over-year growth (+$24.2M vs. prior year), driven by record referrals and record new patient starts.
Profitability and Margin Improvements
Adjusted EBITDA of $15.1M (improvement of $10.7M vs. prior year) and net income of $2.2M (improvement of >$11M vs. prior year); gross margin of 87%, up 2 percentage points YoY.
Raised Full-Year Revenue Guidance
Raised the low end of full-year revenue guidance to $380M–$390M (previously $375M–$390M), implying more than 30% revenue growth for 2026 based on current trends.
Commercial Expansion Executed
Completed planned commercial expansion: sales force increased to ~80 reps and target HCP universe increased to ~12,000 (up from ~7,000–8,000), with expanded patient services and reimbursement support.
Pipeline Progress and XP-8121 Readiness
XP-8121 progressing on schedule with Phase III start anticipated later in 2026; program will leverage XeriSol formulation and device expertise and has multiple abstracts presented this quarter.
Durable Performance from Keveyis
Keveyis revenue of $11.9M, up 4% YoY — second consecutive quarter of YoY growth, demonstrating brand durability in the ultra-rare market.
XERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $6.37 | $6.63 | +4.08% |
Mar 02, 2026 | $6.12 | $6.02 | -1.63% |
Nov 06, 2025 | $9.87 | $7.71 | -21.88% |
Aug 07, 2025 | $5.49 | $6.60 | +20.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Xeris Pharmaceuticals (XERS) earnings time?
Xeris Pharmaceuticals (XERS) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XERS EPS forecast?
XERS EPS forecast for the fiscal quarter 2026 (Q2) is 0.01.